ACE-031 1mg

Research

Scientific Research on ACE-031 (ActRIIB-Fc)
ACE-031 is a recombinant fusion protein composed of the extracellular domain of the activin type IIB receptor (ActRIIB) fused to the Fc portion of human immunoglobulin IgG. It is not a simple peptide but a chimeric protein designed to act as a "ligand trap" receptor, sequestering TGF-β superfamily ligands, particularly myostatin (GDF-8) and related proteins.
It was developed as an experimental agent with potential applications in conditions associated with muscle mass loss or deficiency, such as muscular dystrophies, cachexia, and sarcopenia.

Mechanism of Action and Inhibition

ACE-031 functions as a functional inhibitor of the myostatin pathway through extracellular neutralization of its ligands.
Primary mechanism:

• High-affinity binding to myostatin (GDF-8)
• Binding to other TGF-β family ligands (e.g., activins)
• Prevention of these ligands' interaction with endogenous ActRIIB receptors
• Blockade of SMAD2/3 pathway activation
  Myostatin normally acts as a negative regulator of muscle growth, promoting:
• Inhibition of myogenic differentiation
• Reduction of muscle protein synthesis
• Activation of catabolic pathways
  By sequestering myostatin, ACE-031 promotes:
• Increased muscle mass
• Hypertrophy of muscle fibers
• Potential strength gains
  However, its action is not entirely selective for myostatin, also interfering with other TGF-β superfamily proteins, contributing to adverse effects observed in clinical studies.

Scientifically Investigated Metabolic Impacts

In preclinical models and early clinical studies, the following were observed:

• Significant increases in lean muscle mass
• Relative reductions in body fat in some animal models
• Potential improvements in functional muscle performance
  In animal models, myostatin inhibition was also associated with:
• Improved insulin sensitivity
• Changes in body composition
• Modulation of protein metabolism
  However, systemic metabolic data in humans are limited, as clinical development was discontinued early.

Investigation in Oncological Models

The myostatin/ActRIIB pathway has potential relevance in:

• Cancer-associated cachexia
• Inflammation-induced muscle loss
  In experimental tumor cachexia models, myostatin inhibition demonstrated:
• Preservation of muscle mass
• Reduction of muscle atrophy
• Potential functional improvements
  However, there is no consolidated evidence of direct antitumor effects. Its action focuses on modulating muscle loss secondary to disease.

Pharmacokinetic Considerations in Research

As a fusion protein containing an Fc portion, ACE-031 exhibits:

• Intravenous or subcutaneous administration in experimental protocols
• Prolonged half-life due to FcRn-mediated recycling
• Systemic distribution
• Clearance via protein catabolism
  Early-phase clinical studies demonstrated dose-dependent increases in muscle mass but also revealed adverse events related to interference in vascular and hematological pathways.
  Clinical development was discontinued after observing adverse effects such as epistaxis and telangiectasias, possibly associated with non-selective inhibition of TGF-β family ligands.

Other Important Existing Research Relationships

• Investigation of the myostatin pathway as a therapeutic target
• Development of anti-myostatin monoclonal antibodies
• Study of selective ActRIIB inhibitors
• Potential applications in aging-associated sarcopenia
• Research in Duchenne muscular dystrophy
  Understanding ligand specificity within the TGF-β superfamily became central following the adverse events observed with ACE-031.

Final Considerations

ACE-031 represents a biotechnological strategy based on a "ligand trap" receptor for myostatin neutralization and muscle growth promotion. Although it demonstrated significant muscle mass increases in early studies, its lack of selectivity and systemic adverse effects limited clinical advancement.
From a scientific perspective, it remains relevant as a tool for understanding the ActRIIB/myostatin pathway and developing more selective approaches for muscle growth modulation and cachexia treatment.

References

Lee, S. J. (2012). Regulation of muscle mass by myostatin. Annual Review of Cell and Developmental Biology, 28, 61–83. https://doi.org/10.1146/annurev-cellbio-101011-155836
Campbell, C., McMillan, H. J., Mah, J. K., et al. (2017). Myostatin inhibition in muscular dystrophy. Neurology, 89(2), 127–138. https://doi.org/10.1212/WNL.0000000000004086
Amthor, H., Macharia, R., Navarrete, R., et al. (2007). Lack of myostatin results in excessive muscle growth but impaired force generation. Proceedings of the National Academy of Sciences, 104(6), 1835–1840. https://doi.org/10.1073/pnas.0604893104
Rooks, D., Praestgaard, J., Hariry, S., et al. (2017). Treatment of sarcopenia with a selective androgen receptor modulator and myostatin inhibition. Journal of Cachexia, Sarcopenia and Muscle, 8(6), 933–946. https://doi.org/10.1002/jcsm.12239

Scientific Reviewer
Content reviewed by Dr. Ky H. Le, MD. Dr. Ky H. Le is a family physician in Aiea, Hawaii. He received his medical degree from St. George's University School of Medicine and has been practicing for over 20 years. He has expertise in treating obesity, diabetes, hypertension, and high blood pressure, among other conditions—see all areas of specialization. Dr. Ky H. Le accepts Medicare, Aetna, Humana, Blue Cross, United Healthcare.
Ref.: https://health.usnews.com/doctors/ky-le-371599#expertise